Wells Fargo
MGX icon

Wells Fargo’s Metagenomi Therapeutics MGX Stock Holding History

Wells Fargo’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$452K Buy
379,508
+177,370
+88% +$237K ﹤0.01% 4702
2026
Q1 		$271K Buy
202,138
+83,728
+71% +$130K ﹤0.01% 4516
2025
Q4 		$192K Buy
118,410
+16,402
+16% +$35.5K ﹤0.01% 5093
2025
Q3 		$242K Buy
102,008
+3,612
+4% +$7.33K ﹤0.01% 4827
2025
Q2 		$146K Sell
98,396
-11,572
-11% -$18.1K ﹤0.01% 4957
2025
Q1 		$150K Buy
109,968
+14,780
+16% +$35.2K ﹤0.01% 4871
2024
Q4 		$344K Buy
95,188
+33,582
+55% +$81K ﹤0.01% 4438
2024
Q3 		$134K Buy
61,606
+35,294
+134% +$122K ﹤0.01% 4844
2024
Q2 		$107K Buy
26,312
+1,418
+6% +$9.74K ﹤0.01% 4894
2024
Q1 		$263K Buy
+24,894
New +$286K ﹤0.01% 4297

Other funds holding MGX

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Wells Fargo's MGX Position: Q2 2026 in Review

Wells Fargo increased its Metagenomi Therapeutics (MGX) stake by 88% in Q2 2026, buying an estimated $237K and bringing the position to 379,508 shares worth $452K. The position accounts for ﹤0.01% of the portfolio, ranked #4702.

Wells Fargo first reported a position in MGX in Q1 2024 and has held it in 10 quarters since. 43 funds tracked by Wall St. Rank hold MGX as of Q2 2026.

  • Wells Fargo held 379,508 shares of Metagenomi Therapeutics worth $452K as of Q2 2026.
  • Wells Fargo bought 177,370 Metagenomi Therapeutics shares in Q2 2026, an estimated $237K.
  • Metagenomi Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #4702 holding.
  • Wells Fargo first reported a position in Metagenomi Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • 43 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.